Daniel E Forman1, Karla M Daniels2, Lawrence P Cahalin3, Alexandra Zavin4, Kelly Allsup4, Peirang Cao5, Mahalakshmi Santhanam5, Jacob Joseph6, Ross Arena7, Antonio Lazzari8, P Christian Schulze9, Stewart H Lecker10. 1. New England Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Division of Cardiovascular Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical, School, Boston, Massachusetts. Electronic address: deforman@partners.org. 2. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical, School, Boston, Massachusetts. 3. Department of Physical Therapy, Leonard M. Miller School of Medicine, University of Miami, Miami, Florida. 4. New England Geriatric Research, Education, and Clinical Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts. 5. Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 6. Division of Cardiovascular Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical, School, Boston, Massachusetts. 7. Department of Physical Therapy and Integrative Physiology Laboratory - College of Applied Health Sciences, University of Illinois Chicago, Chicago, Illinois. 8. Division of Rheumatology, Veterans Affairs Boston Healthcare System, Boston, Massachusetts; Boston University School of Medicine, Boston, Massachusetts. 9. Division of Cardiovascular Medicine, Columbia University Medical Center, New York, New York. 10. Boston University School of Medicine, Boston, Massachusetts.
Abstract
BACKGROUND: Declining physical function is common among systolic heart failure (HF) patients and heralds poor clinical outcomes. We hypothesized that coordinated shifts in expression of ubiquitin-mediated atrophy-promoting genes are associated with muscle atrophy and contribute to decreased physical function. METHODS: Systolic HF patients (left ventricular ejection fraction [LVEF] ≤40%) underwent skeletal muscle biopsies (nondominant vastus lateralis) and comprehensive physical assessments. Skeletal muscle gene expression was assessed with the use of real-time polymerase chain reaction. Aerobic function was assessed with the use of cardiopulmonary exercise and 6-minute walk tests. Strength capacity was assessed with the use of pneumatic leg press (maximum strength and power). Serologic inflammatory markers also were assessed. RESULTS: 54 male patients (66.6 ± 10.0 years) were studied: 24 systolic HF patients (mean LVEF 28.9 ± 7.8%) and 30 age-matched control subjects. Aerobic and strength parameters were diminished in HF versus control. FoxO1 and FoxO3 were increased in HF versus control (7.9 ± 6.2 vs 5.0 ± 3.5, 6.5 ± 4.3 vs 4.3 ± 2.8 relative units, respectively; P ≤ .05 in both). However, atrogin-1 and MuRF-1 were similar in both groups. PGC-1α was also increased in HF (7.9 ± 5.4 vs. 5.3 ± 3.6 relative units; P < .05). Muscle levels of insulin-like growth factor (IGF) 1 as well as serum levels of tumor necrosis factor α, C-reactive protein, interleukin (IL) 1β, and IL-6 were similar in HF and control. CONCLUSION: Expression of the atrophy-promoting genes FoxO1 and FoxO3 were increased in skeletal muscle in systolic HF compared with control, but other atrophy gene expression patterns (atrogin-1 and MuRF-1), as well as growth promoting patterns (IGF-1), were similar. PGC-1α, a gene critical in enhancing mitochondrial function and moderating FoxO activity, may play an important counterregulatory role to offset ubiquitin pathway-mediated functional decrements.
BACKGROUND: Declining physical function is common among systolic heart failure (HF) patients and heralds poor clinical outcomes. We hypothesized that coordinated shifts in expression of ubiquitin-mediated atrophy-promoting genes are associated with muscle atrophy and contribute to decreased physical function. METHODS:Systolic HFpatients (left ventricular ejection fraction [LVEF] ≤40%) underwent skeletal muscle biopsies (nondominant vastus lateralis) and comprehensive physical assessments. Skeletal muscle gene expression was assessed with the use of real-time polymerase chain reaction. Aerobic function was assessed with the use of cardiopulmonary exercise and 6-minute walk tests. Strength capacity was assessed with the use of pneumatic leg press (maximum strength and power). Serologic inflammatory markers also were assessed. RESULTS: 54 male patients (66.6 ± 10.0 years) were studied: 24 systolic HFpatients (mean LVEF 28.9 ± 7.8%) and 30 age-matched control subjects. Aerobic and strength parameters were diminished in HF versus control. FoxO1 and FoxO3 were increased in HF versus control (7.9 ± 6.2 vs 5.0 ± 3.5, 6.5 ± 4.3 vs 4.3 ± 2.8 relative units, respectively; P ≤ .05 in both). However, atrogin-1 and MuRF-1 were similar in both groups. PGC-1α was also increased in HF (7.9 ± 5.4 vs. 5.3 ± 3.6 relative units; P < .05). Muscle levels of insulin-like growth factor (IGF) 1 as well as serum levels of tumor necrosis factor α, C-reactive protein, interleukin (IL) 1β, and IL-6 were similar in HF and control. CONCLUSION: Expression of the atrophy-promoting genes FoxO1 and FoxO3 were increased in skeletal muscle in systolic HF compared with control, but other atrophy gene expression patterns (atrogin-1 and MuRF-1), as well as growth promoting patterns (IGF-1), were similar. PGC-1α, a gene critical in enhancing mitochondrial function and moderating FoxO activity, may play an important counterregulatory role to offset ubiquitin pathway-mediated functional decrements.
Authors: P Christian Schulze; Jennifer Fang; Kimberly A Kassik; Joe Gannon; Mihaela Cupesi; Cathy MacGillivray; Richard T Lee; Nadia Rosenthal Journal: Circ Res Date: 2005-07-28 Impact factor: 17.367
Authors: Stewart H Lecker; Alexandra Zavin; Peirang Cao; Ross Arena; Kelly Allsup; Karla M Daniels; Jacob Joseph; P Christian Schulze; Daniel E Forman Journal: Circ Heart Fail Date: 2012-09-20 Impact factor: 8.790
Authors: Thomas K Sin; Bjorn T Tam; Benjamin Y Yung; Shea P Yip; Lawrence W Chan; Cesar S Wong; Michael Ying; John A Rudd; Parco M Siu Journal: J Physiol Date: 2015-02-09 Impact factor: 5.182
Authors: Ali M Tabish; Mohammed Arif; Taejeong Song; Zaher Elbeck; Richard C Becker; Ralph Knöll; Sakthivel Sadayappan Journal: Am J Physiol Heart Circ Physiol Date: 2019-04-26 Impact factor: 4.733
Authors: Carl J Lavie; Ross Arena; Damon L Swift; Neil M Johannsen; Xuemei Sui; Duck-Chul Lee; Conrad P Earnest; Timothy S Church; James H O'Keefe; Richard V Milani; Steven N Blair Journal: Circ Res Date: 2015-07-03 Impact factor: 17.367
Authors: Cholsoon Jang; Sungwhan F Oh; Shogo Wada; Glenn C Rowe; Laura Liu; Mun Chun Chan; James Rhee; Atsushi Hoshino; Boa Kim; Ayon Ibrahim; Luisa G Baca; Esl Kim; Chandra C Ghosh; Samir M Parikh; Aihua Jiang; Qingwei Chu; Daniel E Forman; Stewart H Lecker; Saikumari Krishnaiah; Joshua D Rabinowitz; Aalim M Weljie; Joseph A Baur; Dennis L Kasper; Zoltan Arany Journal: Nat Med Date: 2016-03-07 Impact factor: 53.440
Authors: Leonardo N Moraes; Geysson J Fernandez; Ivan J Vechetti-Júnior; Paula P Freire; Rodrigo W A Souza; Rolando A R Villacis; Silvia R Rogatto; Patricia P Reis; Maeli Dal-Pai-Silva; Robson F Carvalho Journal: Sci Rep Date: 2017-08-01 Impact factor: 4.379